Skip to main
OPRX

OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp (OPRX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

OptimizeRx is positioned for significant growth as the transition from in-person to digital pharma/provider interactions creates new opportunities for revenue expansion in the high teens to low twenties, while also benefitting from improved margins. The company's current headcount is capable of supporting a revenue run-rate of approximately $150 million, indicating substantial operating leverage for the next 2-3 years. Notably, OptimizeRx demonstrated strong financial performance with a record AEBITDA of $12 million, nearly doubling prior estimates and reflecting the effectiveness of its cost management strategies amidst fluctuating revenue.

Bears say

OptimizeRx Corp has reduced its 2026 revenue guidance from $118M-$124M to $109M-$114M, indicating significant near-term challenges, with expectations of negative revenue growth between 10% to 12.5% year-over-year for the first half of the year due to weakened pharma spending amid pricing initiatives. The company's net revenue retention (NRR) has also declined, reflecting reduced investment from large pharma clients, and visibility into future revenue has decreased by 15-20% compared to the previous year. Despite strong gross margins and cost control, the unexpected revenue deceleration and uncertain economic conditions lead to a negative outlook for the stock.

OptimizeRx Corp (OPRX) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptimizeRx Corp (OPRX) Forecast

Analysts have given OptimizeRx Corp (OPRX) a Buy based on their latest research and market trends.

According to 7 analysts, OptimizeRx Corp (OPRX) has a Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptimizeRx Corp (OPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.